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Abstract
Introduction Uveal melanoma (UM) cells and neurohor-
mone-producing cells both originate from the neural crest.
Somatostatin receptors subtype 2 (SSTR2) are over-
expressed in several tumors, often from neuroendocrine
origin, and synthetic antagonists like octreotide and
octreotate are being used as diagnostic or therapeutic
agents. We investigated the SSTR2 expression in UM,
and determined whether this expression was related to
prognosis of the disease.
Materials and methods UM cell lines and fresh primary
UM samples were tested for SSTR2 expression by
autoradiography (AR) using 125I-Tyr3-octreotate. Fur-
thermore, UM cell lines were analyzed for SSTR2
mRNA expression with quantitative real-time RT-PCR.
Results Using AR, cell-surface SSTR2 expression was
demonstrated in two UM metastatic cell lines, but no
expression was detected in three cell lines derived from
primary UM. However, all primary and metastatic UM cell
lines showed mRNA expression levels for SSTR2 using
quantitative real-time RT-PCR. Only three of 14 primary
UM demonstrated moderate SSTR2 expression, and this
expression was not significantly associated with tumor-free
survival or any tested prognostic factor.
Conclusions Based on the rare and low expression of
SSTR2 found in primary UM specimens and in UM cell
lines, we conclude that SSTR2 is not widely expressed in
UM. Furthermore, SSTR2 expression was not associated
with tumor-free survival and prognostic factors. Therefore
SSTR2 is not suited as prognostic marker or therapeutic
target in UM.
Keywords Uveal melanoma . Neurohormone .
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Introduction
Uveal melanoma (UM) is the most common primary
intraocular tumor, with an annual incidence of 0.7/
100,000 in the Western population [1]. Although less than
2% of the patients have clinically detectable metastasis at
presentation, 50% of all patients die due to metastatic
disease. The median survival after the diagnosis of
metastasis is extremely poor. Predictors of survival for
UM patients have been identified in histologic cell type,
tumor diameter, tumor location, age, gender [2, 3], and
cytogenetic parameters. Loss of chromosome 3 is one of the
most significant predictors for uveal melanoma-related
deaths [4–6].
Most of the UM cases are treated by radiotherapy,
thus material for histopathologic and cytogenetic exam-
ination has to be obtained by fine needle aspiration
biopsy (FNAB) for example. Shields et al. showed that
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FNAB provides adequate DNA for genetic analysis of
UM using a microsatellite assay [7]. Early and long-term
complications following intraocular FNAB are rare [8].
Nevertheless, one suspected clinical case of extrascleral
recurrence has recently been reported after diagnostic
intraocular transscleral FNAB [9]. Therefore concern
about tumor seeding due to this diagnostic procedure still
exists [10], and FNAB is consequently not used routinely
yet.
Conversely, neurohormone receptors as markers could
be detected non-invasively and safe using scintigraphy,
without the need to take a biopsy.
During embryogenesis, neural crest cells migrate to the
diencephalon and to the uvea, where they give rise to
pigmented melanocytes. Neural crest cells are able to
produce neurohormones like somatostatin (SST). SST
inhibits the release of growth hormone and thyroid-
stimulating hormone. Its actions are mediated by specific
G protein-coupled receptors, which are located in specific
target cells of the gastrointestinal tract, the peripheral
nervous system and several blood vessels [11].
Moreover, SST could be involved in the inhibition of
tumor growth [12, 13]. SST receptors (SSTR) have been
detected in human neuroendocrine tumors [14–16], human
lung tumors such as bronchial carcinoids [17] and gastro-
entero-pancreatic tumors like insulinomas, gastrinomas, and
ileal carcinoids [18]. SST analogues, like octreotide and
octreotate, can be radiolabelled with radionuclides via a
chelator and are currently being used in the diagnosis
(111In) or therapy (90Y or 177Lu) of patients suffering from
SSTR-expressing tumors [19–22].
Due to the common origin of SST and UM cells, a
relation or interaction may be found. A relation between
eye tissue and neurohormones has already been explored in
several studies [23–25]. In a previous study, Ardjomand et
al. concluded that expression of SST receptors subtype 2
(SSTR2) in UM is correlated with a better ad vitam
prognosis of the patients [26]. Our aim was to further
investigate the expression of SSTR2 in UM, in order to
identify specific membrane receptors for diagnostic imag-
ing and therapeutic targeting. Primary specimens and UM
cell lines, derived from primary or metastatic UM were
analyzed using in vitro autoradiography and quantitative
real-time RT-PCR techniques.
Materials and methods
Patient and tumor material
Informed consent was obtained prior to enucleation and the
study was performed according to the tenets of the
Declaration of Helsinki.
Fresh tumor tissue was obtained within 1 h after enucle-
ation, according to a standardized protocol. An incision was
made through the tumor, leaving the optic nerve intact. A
sample was taken from the side opposite the optic nerve and
divided into two; one part was processed for fluorescent in
situ hybridization (FISH) and another part, as well as control
tissues (rat brain, rat pancreas), were stored in liquid nitrogen
for cryopreservation. Afterwards the remaining tissues were
fixed in 4% paraformaldehyde overnight. Five-micrometer
paraffin sections were cut on a microtome (Microm HM
335E), and put on uncoated slides (Menzel Superfrost)
humidified with sterile water for haematoxylin-eosin (HE)
and periodic acid-Schiff (PAS) staining. Five-micrometer
cryosections of frozen tumor samples and control tissues
were cut on a cryostat (Jung CM3000; Leica, Meyer
Instruments, Inc. Houston, USA), and mounted on coated
slides. Subsequently, the slides were air-dried and stored at
–80°C and processed as below (see under ‘autoradiogra-
phy’). Conventional histopathologic examination was per-
formed on all tumors and confirmed the origin of each one.
Cell lines
Mel202, 92.1 and OCM-1, primary tumor-derived cell
lines, were used as a model for human primary UM.
OMM1 and OMM2.3, skin and liver metastases-derived
cell lines, were used as a model for human UM metastasis.
Rpe1 is a normal retinal pigment epithelium-derived cell
line. OCM-1 was provided by Dr. J. Kan-Mitchell, Mel202
and OMM2.3 by Dr. B. Ksander, 92.1 by Dr. M.J. Jager
and OMM1 and Rpe1 were established in our laboratory
[27–31]. The SSTR-expressing CA20948 cell line originat-
ed from the solid CA20948 rat pancreatic tumor and served
as positive control for autoradiography experiments since
ocreotate detect both rodent and human SSTR2, of which
the homology is more than 90% [19, 32]. All cell lines were
cultured in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% fetal calf serum and 1% penicillin/
streptomycin (GIBCO, Life Technologies, Paisley, UK).
The cells were passaged once or twice a week using trypsin
(0.05%) or trypsin + EDTA (0.02%). Cells were centrifuged
at 1,000 rpm for 10 min in DMEM, resuspended in 0.1 M
DPBS and used to prepare cytospins on coated slides
(Menzel Superfrost Plus Menzel-Gläser, Braunschweig,
Germany) humidified with DPBS using a cytofuge (Nordic,
Tilburg, The Netherlands).
Fluorescent in situ hybridization analysis
Dual-color FISH was performed on uncultured tumor
tissue, by using centromeres, locus-specific cosmids, P1,
or YAC as probes for chromosomes 1, 3, 6, and 8,
respectively, as described previously [33]. Seven probes
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were used: p1–79 (mapped to chromosome band 1p36), P
3.5 (centromere 3), YAC 827D3 (3q24), cos85 (6p21), and
cos52 (6q23) (all from Yusuke Nakamura, Tokyo, Japan)
and D8Z2 (centromere 8) and ETO (8q22). The probes
were validated on normal peripheral blood cell metaphase
spreads, and ten metaphases were analyzed for each probe.
Cutoff limits were less than 3%. The concentration for
centromeric probes was 5 ng per slide; for cosmid, P1, and
YAC probes, 50 to 75 ng per slide was used. After
hybridization and washing, the slides were counterstained
with 4′,6-diamidino-2-phenylindole (DAPI) and mounted in
anti-fade medium (Dabco-Vectashield 1:1; Vector Labora-
tories, Burlingame, CA). Signals were counted in 300
interphase nuclei, according to the criteria of Hopman et al.
[34]. Scoring for deletion (>15% of the nuclei with one
signal) or amplification (>10% of the nuclei with three or
more signals) was adapted from the available literature [35].
Autoradiography
125I-DOTA-Tyr3-octreotate (BioSynthema, St. Louis Mo,
USA), that has a high affinity binding to SSTR2, was used
for the autoradiography study [36]. The autoradiographic
experiments were performed on cryosections and cytospins
using 10–9M or 10–10M 125I-DOTA-Tyr3-octreotate, with or
without a blockade of 10–6M unlabelled octreotide (Novartis,
Basel, Switzerland), to investigate SSTR2 specific binding as
described in literature [14, 37]. After 1 h incubation at room
temperature and rinsing with Tris buffer to remove the non-
bound radioactive octreotate, dried cryosection, and cytospin
slides were exposed to phosphor-imaging screens (Packard
Instruments Co., Meriden, USA) in X-ray cassettes. After 24–
72 h, the screens were read using a Cyclone phosphor imager
and analyzed with OptiQuant 03.00 image processing system
(Packard Instruments Co., Groningen, The Netherlands).
Binding of 125I-DOTA-Tyr3-octreotate to cytospins and
cryosections was expressed in digital light units (DLU)/
mm2. Net DLU/mm2 represents binding of 125I-DOTA-Tyr3-
octreotate (specific binding) minus non-specific binding in
adjacent sections incubated with 125I-DOTA-Tyr3-octreotate
plus 10–6M octreotide. Net DLU/mm2 was considered
positive when >5,000 DLU/mm2.
Quantitative real-time RT-PCR
SSTR2 mRNA expression was analyzed by quantitative
real-time-reverse transcriptase–polymerase chain reaction
(real-time RT-PCR). RNA was isolated using an RNeasy®
Mini Kit (Qiagen, Valencia, USA). RNA samples were
stored at –80°C until further processing. Approximately
1 μg of RNA per sample was reverse-transcribed using the
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). The
20-μl solutions obtained this way were diluted by adding
sterile water up to 100 μl. In 96-wells, 2 μl of this solution
was added to a 15-μl solution of iQ SYBR Green
Supermix, forward and reverse primers (10 μM solutions)
for SSTR2 or RPS-11 (control gene) and sterile water
(volume ratio, respectively, 10:1:1:8). The primers had the
f o l l o w i n g s e q u e n c e s : S S TR 2 f o r w a r d 5 ′ -
TGCTGGGTCTGCCTTTCTTGG – 3′, SSTR2 reverse 5′ –
AGAAGATGCTGGTGAACTGATTGATG – 3′, RPS-11
forward 5′ – AAGCAGCCGACCATCTTTCA – 3′, RPS-
11 reverse 5′ – CGGGAGCTTCTCCTTGCC – 3′ [38]. A
quantitative analysis of the samples was then performed for
SSTR2 and RPS-11 (control gene) expression by real-time
RT-PCR in a MyiQ iCycler real-time PCR system (Bio-
Rad, Hercules, CA). The PCR reaction settings were 95°
for 5 min, then 40 cycles at 96° for 15 s and 60°C for 45 s.
DNA melting peaks were acquired by measuring the
fluorescence of SYBR Green during a linear temperature
transition from 70°C to 97°C at 0.2°C each 10 seconds with
accompanying software (Bio-Rad Laboratories BV). To
correct the sample-to-sample variation when determining
gene expression, an accepted method is to select a cellular
housekeeping gene that serves as an endogenous control,
against which the target gene expression levels can be
normalized [39]. RPS-11 (ribosomal protein S11) is a
housekeeping gene that has recently been introduced to
normalize gene expression in UM cells [40].
Results
Patients and tumor material
In total, primary UM from 14 patients (ten male and four
female, with a mean age of 63±10.1 years) were included
in the study. Histopathologic analysis of HE and PAS
stained paraffin sections was performed on all primary UM.
The mean tumor diameter was 12.6±2.8 mm and their
mean prominence was 8.5±2.0 mm. Epithelioid cells were
found in ten of 14 cases, while in seven cases vascular
loops and/or networks were detected. Furthermore, FISH
analysis of all samples was performed; monosomy 3 as well
as loss of chromosome 1p was found in 10 of 14 cases and
gain of chromosome 8q was present in 7 of 14 cases. After
a mean follow-up period of 36.1±13.0 months, five patients
had developed distant metastases (Table 1).
Autoradiography
Fresh primary UM samples were tested for expression of
SSTR2 by AR using 125I-Tyr3-ocreotate. In three of the 14
primary UM, a positive (albeit weak) binding was observed
(Table 2). Statistical analysis with the Kaplan–Meier
method and log-rank test did not show any significant
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relation between SSTR2 expression and tumor-free survival
(p=0.76). In the univariate and multivariate Cox-regression
analysis, SSTR2 expression was not significantly associat-
ed with tumor-free survival or other important prognostic
factors (cell type, vascular patterns, tumor diameter,
prominence, monosomy 3, loss of chromosome 1p and
gain of chromosome 8q).
UM cell lines were also tested for expression of SSTR2
by AR using 125I-Tyr3-ocreotate. All cell lines were tested
in duplicate.
The positive control rat pancreatic tumor cell line
(CA20948) showed a strong binding. Cell line 92.1 showed
very low binding while none of the other primary UM
derived cell lines (Mel202, OCM-1) or normal cell line
(Rpe1) showed specific receptor binding. Both metastatic
UM cell lines (OMM1, OMM2.3) showed high binding
(Fig. 1, Table 3).
Quantitative real-time RT-PCR in cell lines
Expression of SSTR2 mRNA in UM cell lines was
evaluated by real-time RT-PCR, with normalization of the
expression levels to the housekeeping gene RPS-11. All
Table 2 Autoradiography results of primary uveal melanoma samples
Metastasis1 Autoradiography2
125I-Tyr3-Ocreotate (SSTR2)
1 - ++
2 - +
3 + +
4 - -
5 - -
6 - -
7 + -
8 - -
9 + -
10 + -
11 + -
12 - -
13 - -
14 - -
Control NA3 ++++
1Metastasis present: +, No metastasis:-
2 Netto Digital Light Units/mm2 : <5,000: –, 5,000–10,000: +, 10,000–
50,000: ++, 50,000–100,000: +++, >100,000: ++++
3Not applicable
Table 1 Clinical, histopathologic, and genetic data of included
patients
Sex (male/female) 10/4
Age (mean±SD, years) 63.0±10.1
Diameter (mean±SD, mm) 12.6±2.8
Prominence (mean±SD, mm) 8.5±2.0
Cell type (epithelioid/non-epithelioid) 10/4
Vascular loops and/or networks (yes/no) 7/7
Pigmentation (yes/no) 8/6
Metastasis (yes/no) 5/9
Monosomy 3 (yes/no) 10/4
Loss of 1p (yes/no) 10/4
Gain of 8q (yes/no) 7/7
Follow-up (mean±SD, months) 36.1±13.0
Fig. 1 Autoradiogram of cytospins of several uveal melanoma cell
lines and controls demonstrating SSTR2 expression 1st column: 125I-
Tyr3-ocreotate 2nd column: 125I-Tyr3-ocreotate + excess octreotide A.
OMM2.3, B. OMM1, C. Mel202, D. OCM-1, E. Rpe 1, F. CA20948,
G. Rat brain section (a few cell lines are shown in duplicate)
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five UM cell lines tested expressed SSTR2 mRNA, but the
level of expression was quite variable. OMM2.3 showed a
two to four times higher expression level of SSTR2 mRNA
compared to the other metastases derived UM cell line
OMM1, and the primary UM cell lines 92.1 and Mel202.
The other tested primary UM cell line OCM-1 showed a
very low SSTR2 mRNA expression level (Fig. 2).
Discussion
Expression of somatostatin receptors in neuroendocrine
tumors has been extensively investigated and led to the
development of clinically relevant diagnostic and therapeu-
tic strategies. Based on common embryonic origin, uveal
melanoma could also be a candidate for such strategies, as
many patients die from metastasized UM.
In this study, SSTR2 expression was studied in 14
primary UM tumor samples and several different UM cell
lines, either derived from primary or from metastasized UM
tumor samples. Primary tumors were tested at the protein
level using in vitro autoradiography, cell lines were
additionally analyzed on mRNA level with quantitative
real-time RT-PCR. In only three primary specimens
moderate SSTR2 expression was demonstrated. One of
these was a metastasized UM, while four other samples of
metastasized UM did not express SSTR2.
Furthermore, the relation between SSTR2 expression,
tumor-free survival and prognostic factors was studied,
although the number of samples we used was too small to
perform reliable statistical analysis. With the data obtained
thus far, no significant correlation between SSTR2 expres-
sion and tumor-free survival or any other important
prognostic parameter could be found. Conversely, Ardjo-
mand et al. detected SSTR2 expression in nearly all of 25
tested samples, using immunohistochemistry on paraffin
embedded UM tissue. When the prognosis of these 25
patients was compared with the expression level of SSTR2
in uveal melanoma tissue, a positive correlation was found
between high SSTR2 and a better ad vitam prognosis [26].
Since Ardjomand et al. used a different approach and
techniques to determine SSTR2 expression, it is difficult to
compare our results. An explanation for the differences
could be that we used cryosections instead of paraffin
sections, in antibody versus peptide targeting. Furthermore,
in immunohistochemistry it is possible to discriminate
positive staining in individual cells by using antibodies
for specific subtypes of somatostatin receptors. In our AR
experiments, we analyzed tissue cryosections and a peptide
analogue that can be applied in vivo for PET or SPECT
imaging, after labelling with an appropriate radionuclide. In
AR a certain threshold had to be reached before tissue
could be identified as positive; however, this threshold is
low due to the high sensitivity of the phosphor imaging
read out system. For in vivo imaging this threshold would
be much higher. Most of the tumors tested by Ardjomand et
al. contained between 11 and 80% of SSTR2 expressing
tumor cells. If the percentage of SSTR2 expressing tumor
cells in our tested specimens was within this range, these
should have been detected using in vitro autoradiography.
Furthermore, Ardjomand et al. also argued the diagnostic
value of SSTR expression, since in only two of four
patients with UM in their study the affected eye could be
visualized by octreotide scintigraphy.
Besides primary UM samples, UM derived cell lines,
originating either from primary or from metastasized UM
tumors, were tested for SSTR2 expression. By using the in
vitro AR technique with cytospins of UM cell line cells, it
was found that three primary UM melanoma cell lines
showed almost no specific binding of 125I-Tyr3-octreotate,
Table 3 Autoradiography results of uveal melanoma cell lines
Cell line Autoradiography1
125I-Tyr3-Octreotate (SSTR2)
Primary 92.1 +
Mel202 -
OCM-1 -
Metastatic OMM1 ++
OMM2.3 ++
Normal Rpe2 Rpe1 -
Control CA20948 3 ++++
1 Netto Digital Light Units/mm2 : <5,000: –, 5,000–10,000: +,
10,000–50,000: ++, 50,000–100,000: +++, >100,000: ++++
2Normal retinal pigment epithelium cell line
3 Control cell line from the solid CA20948 rat pancreatic tumor
Fig. 2 Expression of SSTR2 mRNA in uveal melanoma cell lines. All
five UM cell lines tested expressed SSTR2 mRNA. The expression
levels were normalized to the housekeeping gene RPS-11. OMM2.3
shows a two to four times higher expression level of SSTR2 mRNA
compared to OMM1, 92.1 and MEL202. Primary UM cell line OCM-
1 had a very low expression level, and can therefore not be compared
to the other UM cell lines
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whereas both metastatic UM cell lines showed strong
binding. This implied that expression of SSTR2 at the
protein level could be associated with a bad prognosis and
development of metastasis. This clear SSTR2 expression of
the metastatic UM cell line OMM2.3 correlated with a four-
times-higher expression level of SSTR2 mRNA compared
to the primary UM line 92.1 in quantitative real-time RT-
PCR. The primary UM cell line Mel202 also showed a
moderately high SSTR2 mRNA expression, but apparently
this mRNA was not transcribed to protein. The correlation
between SSTR2 expression at mRNA and protein level
seems to be good in cell lines derived from metastasized
UM, but less in lines from primary UM. Furthermore, there
is a discrepancy between the SSTR2 expression in cell lines
compared to that in primary and metastasized uveal melano-
ma specimens, in which only a small percentage of low
SSTR2 expressing samples was found. Expression of high
SSTR2 levels might be favorable for deriving an in vitro
growing cell line from an UM biopsy. Thus cell lines might
not be really representative for in vivo circumstances [41].
Considering the low SSTR2 expression of the primary
UM samples, we conclude that imaging with somatostatin
analogues to perform scintigraphy is not feasible in uveal
melanoma patients.
Although FNAB has been shown to accurately demon-
strate genetic and histologic prognostic factors in the
obtained tissue [7], finding another tumor-specific (neuro-
hormone) receptor that can be used as an in vivo target for
diagnosis (and therapy) is still an attractive, non-invasive
option to improve the diagnosis of (metastasized) UM using
specific radiolabelled peptide analogues. Metastasis is the
single leading cause of death of patients with UM. Kaplan–
Meier estimates of 5-year melanoma-related mortality range
from 26 to 32% [42]. The first site of metastasis is the liver
in approximately 90% of patients, but later spread to the
lungs, bone, and skin occurs frequently [43–45]. It remains
unknown to which extent current treatments for metastasis
actually prolong survival compared to no treatment at all
[46, 47]. It is proposed that patients who develop clinical
metastases from uveal melanoma often harbor micro
metastases for years [48]. Targeting tumor-specific recep-
tors might be used to treat these (micro) metastases in
future when specific analogues are radiolabelled with
therapeutic β-emitting radionuclides like 177Lu.
Further investigation targeting other neural-crest derived
hormone receptors may thus reveal new options. Several
studies have shown that vasoactive intestinal peptide (VIP)
and pituitary adenylate-cyclase-activating polypeptide
(PACAP) have tumor-growth promoting activities in breast
cancer and neuroblastoma for example. Furthermore, VIP
and PACAP antagonists demonstrated growth-inhibitory
properties [49–52]. VIP receptors have been found to be
ubiquitous expressed in all ocular tissues, with highest
concentrations occurring in the choroid of several different
mammals [23]. Most UM are strongly pigmented. Alpha-
melanocyte-stimulating hormone is primarily responsible
for the regulation of pigmentation and could therefore be
linked to UM [53].
In conclusion, additional exploration of neurohormone
receptors is needed to identify a specific membrane receptor
to be used in diagnostic imaging and therapeutic targeting.
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